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Summary
Fumaric acid esters (FAEs) are licensed for the treatment of moderate-to-severe pso-
riasis in Germany but are also used off-label in many other countries. We con-
ducted this systematic review to synthesize the highest-quality evidence for the
benefits and risks of FAEs for psoriasis. Our primary outcomes were change in Pso-
riasis Area and Severity Index score and dropout rates due to adverse effects. Ran-
domized controlled trials (RCTs) of FAEs or dimethylfumarate were included, with
no restriction on age or psoriasis subtype. We searched the Cochrane Skin Group
Specialised Register, CENTRAL in the Cochrane Library, Medline, Embase, LILACS
and five trials registers, and hand searched six conference proceedings. Six RCTs
with a total of 544 participants were included, four of which were published only
as abstracts or brief reports, limiting study reporting. Five RCTs compared FAEs
with placebo, and all demonstrated benefit in favour of FAEs. However, meta-ana-
lysis was possible only for PASI 50 response after 12–16 weeks, which was
achieved by 64% of participants on FAEs compared with 14% on placebo: risk ratio
(RR) 455, 95% confidence interval (CI) 280–740; two studies; 247 participants;
low-quality evidence). There was no difference in dropout rates due to adverse
effects (RR 536, 95% CI 028–10212; one study; 27 participants; very low-quality
evidence and wide CI). More participants experienced nuisance adverse effects with
FAEs (76%) than with placebo (16%) (RR 472, 95% CI 245–908; one study; 99
participants; moderate-quality evidence), mainly abdominal pain, diarrhoea and
flushing. One head-to-head study of very low-quality evidence comparing FAEs
with methotrexate reported comparable efficacy and dropout rates, although FAEs
caused more flushing. The evidence in this review was limited and must be inter-
preted with caution; studies with better design and outcome reporting are needed.
What’s already known about this topic?
• Fumaric acid esters (FAEs) are licensed for the treatment of moderate-to-severe
psoriasis in Germany, and are used off-label in many other countries.
• Non-Cochrane systematic reviews previously examined the effect of FAEs in psoria-
sis, but have not rigorously assessed the quality of the evidence.
What does this study add?
• Six randomized controlled trials with 544 participants were included, four of
which were published only as abstracts or brief reports, resulting in low- or very
low-quality evidence.
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• Results suggest that FAEs are superior to placebo, but their efficacy in comparison
with methotrexate is uncertain due to very low-quality evidence.
• The relative risk of nuisance adverse effects with FAEs is about five times greater
than with placebo; however, there is insufficient evidence available to give an accu-
rate figure for dropout rates due to adverse effects.
Psoriasis is a chronic inflammatory skin disease with various
subtypes, of which chronic plaque psoriasis is the most com-
mon.1 Fumaric acid esters (FAEs) were first used in the treat-
ment of psoriasis in 1959 after successful self-experimentation
by Schweckendiek, a German chemist who proposed that psori-
asis was caused by a disturbance in the citric acid cycle in which
fumaric acid was lacking.2 FAEs contain dimethylfumarate
(DMF), believed to be the active component, and salts of ethyl
hydrogen fumarate.3 Fumaderm Initial (Biogen Idec, Cam-
bridge, MA, U.S.A.), containing 30 mg of DMF per tablet, and
Fumaderm, containing 120 mg of DMF per tablet, are com-
mercially available and have been licensed for the treatment of
psoriasis in Germany since 1994.4 They are also used for psori-
asis treatment as off-label drugs in many other countries. The
aim of this Cochrane review was to provide the best available
evidence for the efficacy and safety of FAEs in the treatment of
psoriasis. The results are summarized in this report, and the full
review is available in the Cochrane Library.5
Material and methods
This systematic review was carried out according to a
prespecified protocol6 and incorporated Grading of Recom-
mendations Assessment, Development and Evaluation (GRADE)
methodology.7
Search strategies
An electronic search for relevant studies was carried out up to
May 2015 using the Cochrane Skin Group Specialised Register,
the Cochrane Central Register of Controlled Trials (CENTRAL)
in the Cochrane library, Medline via Ovid from 1946, Embase
via Ovid from 1974, and the Latin American and Caribbean
Health Science Information (LILACS) database from 1982. We
also searched the following trial registers up to May 2015
using the search terms ‘fumaric acid’, ‘fumarate’ and ‘fuma-
derm’: the metaRegister of Controlled Trials (http://www.
isrctn.com/page/mrct), The US National Institute of Health
Ongoing Trials Register (www.clinicaltrials.gov), The Aus-
tralian New Zealand Clinical Trials Registry (www.anzctr.or-
g.au), The World Health Organization International Clinical
Trials Registry platform (www.who.int/trialsearch) and the
EU Clinical Trials Register (https://www.clinicaltrialsregis-
ter.eu/).
Abstracts of proceedings not included in electronic registries
from the following dermatology conferences were hand
searched by two authors independently (A.A. and R.A.):
American Academy of Dermatology (2008/2009), British
Association of Dermatologists (2008–2010) European Acad-
emy of Dermatology and Venereology (May 2006 to May
2013), European Society for Dermatological Research
(2005–2009), International Investigative Dermatology (2003
to May 2013) and Society for Investigative Dermatology
(2007–2009). The reference lists of included and excluded
studies were checked for further references to relevant trials.
We included all relevant randomized controlled trials (RCTs),
with no language restrictions.
Inclusion criteria
We included RCTs that involved participants of either sex, and
any age or ethnicity, with a clinical diagnosis of psoriasis of
any subtype, where FAEs, as monotherapy or in combination,
were compared with placebo or any other active treatment.
Types of outcome measures
The primary outcomes were Psoriasis Area and Severity Index
(PASI) score and dropout rates due to adverse effects. Other
outcomes of interest were quality-of-life scores measured with
a validated scale; the proportion of participants achieving
≥ 50%, ≥ 75% and ≥ 90% improvement in PASI (PASI 50, 75
and 90); the proportion of participants experiencing serious
adverse effects and those experiencing nonserious nuisance
adverse effects.
Data extraction and synthesis
The titles and abstracts of retrieved studies were screened by
two authors independently (A.A. and R.A.). The full texts of
potentially eligible studies were examined by the same authors
who extracted data from eligible studies using a data extrac-
tion form based on the ‘checklists of items to consider in data
extraction’;8 a third author (J.R.I.) adjudicated on
disagreements.
Review Manager,9 the software used for Cochrane reviews,
was used for statistical analysis with a fixed-effects model. For
dichotomous outcomes we pooled risk ratios (RRs) with 95%
confidence intervals (CIs), while we combined the mean dif-
ference (MD) with 95% CI for continuous outcomes. We
made contact with trial authors whenever possible to request
relevant unreported data. Statistical heterogeneity was assessed
using I2 statistics; we took a narrative approach if the I2 value
exceeded 75%.10 The quality of evidence for each outcome
was ranked using GRADEpro software, from which we pro-
duced our ‘summary of findings’ tables.7
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Results
Description of the included studies
In total, 94 records were identified through the initial search:
database searching (n = 80), hand searching (n = 6) and trials
registers (n = 8) (Fig. 1). These included eight ongoing stud-
ies and eight duplicate reports, which were excluded, giving a
total of 78 records. Of these, 11 potentially eligible studies
were identified after screening the titles and abstracts. After
reading the full texts, five articles were excluded due to failure
to meet our prespecified inclusion criteria11–14 and lack of evi-
dence of randomization.15 As a result, six studies with a total
of 544 participants were included in our review; five com-
pared FAE with placebo16–20 and one used methotrexate as an
active comparator.21
The included studies were reported between 1990 and
2011. Only two of the six studies were published in full
reports,16,21 whereas the others were available in a brief com-
munication,19 a letter20 and abstracts.17,18 We were unable to
obtain the full reports of published abstracts by contacting the
authors. Despite the limitations of incompletely reported stud-
ies, we decided it was important to include them in our
review because of the limited number of eligible RCTs.
Three of the included studies were carried out in the
Netherlands,19–21 one of which was designed to measure the
effect of FAEs in the treatment of psoriatic arthritis.20 How-
ever, contact with the authors confirmed that all participants
had concomitant psoriasis, so we included this study to obtain
safety data. All of the included studies involved adults aged
> 18 years, except one study that did not report the partici-
pants’ ages.17 Participants in the included studies had chronic
plaque psoriasis in two studies;18,21 various psoriasis subtypes
in two studies (chronic plaque, guttate, pustular and erythro-
dermic)16,17 and unreported psoriasis subtype in two stud-
ies.19,20
PASI score at baseline was reported in only three studies,
and was required to be ≥ 10 in one study,21 ≥ 12 in one
study18 and 16–24 in one study.17 Outcome reporting was at
12–16 weeks in all of the included studies, but not all of our
prespecified outcomes were reported in every study. None of
the included studies reported data on economic evaluations.
Risk of bias in the included studies
Three of the included studies had ‘high risk’ of bias in at least
one domain.16,17,21 Insufficient reporting in most of the
included studies, due to lack of full reports and old publica-
tions, rendered the risk of bias for most domains ‘unclear’
(Fig. 2).
Effects of interventions
Due to the lack of opportunities for meta-analyses, we used
mainly a narrative approach to present the effects of FAEs in
the treatment of psoriasis. The only exception was for the
secondary outcome PASI 50 when FAEs were compared with
placebo, where data from two studies were combined.
Comparison of fumaric acid esters with placebo
Three of the five studies comparing FAEs with placebo used a
mixture of DMF plus monoethylfumarate as an interven-
tion,16,19,20 whereas DMF alone was used in the other two
studies.17,18 Two of the included studies17,18 were reported in
abstracts only; contact with the lead author18 confirmed that
the studies were not reported in full manuscripts and only the
Fig 1. Study flow diagram.
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data contained in the abstracts are available. In view of the
limited number of eligible studies, and in agreement with the
Cochrane Editorial Unit, we included these abstracts in our
review. The quality of evidence for each outcome is presented
in Table 1.
Altmeyer et al.16 reported a reduction of PASI score from a
mean of 2157 at baseline to 1077 after 16 weeks of FAE
treatment, whereas in the placebo group it remained the same
(P < 0001). Langner et al.17 compared three doses of FAE
(120 mg, 360 mg, 720 mg) with placebo, and reported sta-
tistically significant reductions in PASI score after 12 weeks,
compared with baseline, of 31%, 52% and 71%, respectively
(P < 0001 compared with placebo for the 360-mg and 720-
mg doses). Similarly, Mrowietz et al.18 reported a median PASI
score of 58 after 16 weeks of FAE treatment (n = 105), com-
pared with a median of 142 in the placebo group (n = 70)
(P < 0001). This represented 678% and 102% reductions,
respectively, and an effect size of 74 points (95% CI 540–
940). It was not possible to compute the MD in these studies
because of unreported mean PASI scores at baseline and
follow-up.
In a meta-analysis from two studies17,18 including a total of
247 participants, the number of participants who attained PASI
50 was greater with FAEs than with placebo (RR 455, 95%
CI 280–740; P < 0001; I2 = 0%; low-quality evidence)
(Fig. 3). The combined PASI 50 was 64% with FAEs, com-
pared with 14% for placebo, representing a number needed to
treat to benefit (NNTB) of 2. The other studies comparing
FAEs with placebo did not include a PASI score and instead
measured the disease severity by estimating the body surface
area involved.19,20
The dropout rate due to FAE adverse effects was reported
clearly in only one study, which was designed for psoriatic
arthritis.20 In this study, two withdrawals occurred in the FAE
group (n = 13) compared with no dropouts in the placebo
arm (n = 14) (RR 536, 95% CI 028–10212; 27 participants;
very low-quality evidence). However, this finding is unreliable
due to indirectness and very wide CIs. The reasons for drop-
out in the FAE group were diarrhoea (after 6 weeks) and pro-
teinuria with raised serum creatinine (after 12 weeks). We
could not establish the RR of dropouts due to adverse effects
alone in the other studies because of unclear16,19 or lack17,18
of reporting. None of the included studies reported whether
the adverse effects that led to treatment discontinuation were
serious.
One study16 reported a higher incidence of nuisance
adverse effects (not leading to treatment discontinuation) with
FAEs compared with placebo (RR 472, 95% CI 245–908;
99 participants; moderate-quality evidence), affecting 76% of
participants given FAEs (n = 49) and 16% of the placebo
group (n = 50), representing a number needed to treat to
harm of 2. The most common were abdominal pain,
diarrhoea and flushing (percentage and RR could not be
computed).
A within-group comparison showed a statistically signifi-
cant decrease of leucocytes with FAEs (P = 0016), due to a
reduction in lymphocyte count. The eosinophil count was
unchanged in the placebo group, and increased in the FAE
group from 2% at baseline to 34% at 4 weeks (P < 005),
with a further insignificant increase to 47% at week 12.
The maximum increase in eosinophil count was 28% (time
point not stated). Another study19 with a small number of
participants in the FAE group (n = 13) reported diarrhoea
(100% of participants), flushing (95%) and nausea (46%)
as the most common adverse effects. Increased serum crea-
tinine to 238 lmol L1 and reduced creatinine clearance
rate by 51% were reported in one participant (8%) in the
FAE group, but this was reversible (unknown whether
treatment was stopped prior to improvement of the renal
function).
Transient increase in liver enzymes (62%), eosinophilia
(38%) and lymphopenia (31%) were also reported with FAEs,
but it was not clear whether these occurrences were serious
or caused treatment discontinuation. In the abstract published
by Mrowietz et al.,18 gastrointestinal adverse effects were
observed in 58% of participants in the FAE group (n = 105),
compared with 23% of those given placebo (n = 70) (RR
254, 95% CI 160–403). Adverse effect severity was
described as moderate in 82% of cases (unclear whether any
of the remaining 18% dropped out due to severe symptoms).
In this abstract, more participants experienced flushing with
FAEs in comparison with placebo (42% vs. 9%) (RR 467,
95% CI 209–1039).
Quality of life was reported in only one abstract, using
Skindex-29.18 The mean score in the FAE group decreased
from 547 at baseline to 270 at week 16, in comparison with
Fig 2. Risk-of-bias graph: review authors’
judgements about each risk-of-bias item
presented as percentages across all included
studies.
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a reduction from 540 to 511 in the placebo arm, a between-
group difference of 193 points (P < 0001).
Comparison of fumaric acid esters with methotrexate
Only one study, involving 60 randomized participants, com-
pared FAEs with methotrexate in an open-label fashion.21
Thirty participants were assigned to each group, of whom 26
of the FAE group and 25 in the methotrexate group were
included in the primary analysis at week 12. The quality of
evidence for each outcome is summarized in Table 2.
The study reported similar efficacy of FAE and methotrex-
ate, with a mean PASI score reduction from 145 at baseline
to 67 after 12 weeks in the methotrexate group (n = 25) in
comparison with a reduction from 181 to 105 in the FAE
group (n = 26). The reported absolute difference after adjust-
ment for baseline values was 14 (95% CI 20 to 47;
P = 042). However, when we compared the PASI scores at
follow-up (week 12), as recommended by The Cochrane Col-
laboration, there was a significant difference in favour of
methotrexate (MD 380, 95% CI 068–692; very low-quality
evidence) (Fig. 4).
No significant difference was noted between the two groups
in the numbers of participants who attained PASI 50 (RR
071, 95% CI 041–122; very low-quality evidence), PASI 75
(RR 080, 95% CI 028–229; very low-quality evidence) and
PASI 90 (RR 048, 95% CI 005–498; very low-quality evi-
dence). However, the maximum dose of methotrexate used in
this study (15 mg per week) may have been suboptimal, as
higher doses can be prescribed in routine clinical practice.
Also, the time of assessment at 12 weeks might have been too
early to evaluate true efficacy. Although the study reported no
significant difference in the number of participants attaining
PASI 75 and PASI 90 at week 16, it must be noted that the
dose of methotrexate was reduced gradually from week 12,
which may have reduced the effect size.
The dropout rate due to adverse effects in both groups was
not significantly different (RR 019, 95% CI 002–153; very
low-quality evidence) (Fig. 5). Four participants (16%) in the
methotrexate group dropped out because of elevated liver
enzymes; another patient dropped out due to recurrent angina
unrelated to treatment. Raised liver enzymes were reported to
be transient, and normalized 4–8 weeks after treatment
discontinuation. Only one participant in the FAE group (4%)
discontinued treatment, due to diarrhoea.
Overall, the number of participants experiencing nuisance
adverse effects was not significantly different between the two
groups (RR 089, 95% CI 077–103; very low-quality evi-
dence). However, more participants experienced flushing in
the FAE group (13 vs. two) (RR 650, 95% CI 162–2609).
There was no significant difference in reported laboratory
findings between the two groups, which may reflect the small
study size. Transient increase of liver enzymes (up to double
the baseline value) was observed in 11% of participants in the
FAE group and 30% of participants given methotrexate (RR
038, 95% CI 011–126). There was transient eosinophilia
(maximum measured level 155 9 109 cells L1) in five par-
ticipants in the FAE group, compared with none of those on
methotrexate (RR 1100, 95% CI 064–18965), and transient
leucocytopenia (21 9 109 cells L1) in one participant in the
FAE group, compared with none in the methotrexate group
(RR 300, 95% CI 013–7053). An equal number of eight
participants from each group (30%) showed transient protein-
uria (RR 100, 95% CI 044–228).
Discussion
Limited evidence suggests that FAEs are superior to placebo in
the treatment of psoriasis, and there is very low-quality evi-
dence to determine the relative efficacy of FAEs compared
with methotrexate. Commonly reported adverse effects associ-
ated with FAEs include gastrointestinal symptoms (58% of
participants in one study), flushing (42%, 48% and 95% in
three studies), eosinophilia (19% and 38% in two studies)
and reversible proteinuria (30% in one study). However, the
evidence provided by this review was limited due to a lack of
full reports and inconsistencies of reporting. No long-term
studies were identified to comment on the long-term efficacy
and safety of FAEs in psoriasis.
The small number of included studies and insufficient
reporting of outcomes were major limitations to address the
objectives of our review. Some studies included participants
with various types of psoriasis, but the outcomes reported did
not indicate whether the response to FAEs varied between dif-
ferent subgroups. The majority of studies comparing FAEs
with placebo did not report the number of participants who
Fig 3. Comparison: fumaric acid esters (FAEs) vs. placebo. Outcome: ≥ 50% improvement in Psoriasis Area and Severity Index. CI, confidence
interval.
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dropped out because of adverse effects. Variation in FAE dose
increments may also have had an impact on the magnitude of
treatment benefit and risk of adverse effects. More recently,
the European S3 psoriasis guidelines have standardized the
schedule of dose increments,22,23 which may help to inform
future FAE trial designs. We were unable to establish whether
the use of DMF alone has a similar efficacy and safety profile
to the mixture of DMF plus monoethylfumarate.
Other non-Cochrane systematic reviews have also reported
the superiority of FAEs over placebo in the treatment of psori-
asis,24–26 and similar efficacy to methotrexate.24,26 However,
GRADEpro assessment of the level of quality of evidence in
our review demonstrated that the latter conclusion is unreli-
able due to the very low quality of evidence. There is a rela-
tive paucity of RCTs comparing other conventional oral
treatments for psoriasis with placebo.
Bansback et al.27 reported in meta-analyses an RR of PASI
50 response of 474 with methotrexate 15–225 mg weekly
(95% CI 352–573), with an NNTB of 2; and 406 with
ciclosporin 3 mg kg1 per day (95% CI 254–573), with
an NNTB of 2. These are comparable with our findings of
FAE efficacy with a PASI 50 RR of 455 compared with pla-
cebo (95% CI 280–740) and an NNTB of 2. However,
the dropout rates and risk of adverse effects were not
reported by Bansback et al. Three RCTs from the 1980s28–30
demonstrated that acitretin 50–75 mg daily was significantly
better than placebo and a lower acitretin dose (10–25 mg
daily) in treating psoriasis, but no PASI scores were
reported and the dropout rate due to adverse effects was
unclear. A Cochrane systematic review is currently underway
to examine all systemic pharmacological interventions for
psoriasis.31
Most of the studies included in our review were not fully
reported and were performed before the requirement of trial
registration. As a result we downgraded the evidence quality
to low or very low. The findings in our review reinforce the
conclusion of the European S3 guidelines that ‘although the
use of fumarates for psoriasis has been evaluated in clinical tri-
als, only a small number of these have followed the criteria of
evidence-based medicine’.22 Our review also highlights the
inadequate reporting of adverse effects, which should be based
on the Consolidated Standards of Reporting Trials (www.con-
sort-statement.org). Application of these standards and consis-
tency in reported outcomes based on the Core Outcome
Measures in Effectiveness Trials initiative are necessary to
enhance the quality and robustness of evidence in future FAE
trials. There remains a need to establish the long-term safety
of FAEs, an evidence gap that is being addressed by the British
Association of Dermatologists’ Biologic Interventions Regis-
ter32 and other psoriasis databases.
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